QIAGEN is under pressure after issuing preliminary first-quarter 2026 results alongside a reduced full-year outlook. The company said preliminary Q1 net sales were $492 million, up 2% year over year on a reported basis but down 1% at constant exchange rates, missing its prior outlook for at least 1% constant-currency growth. Despite meeting its adjusted diluted EPS outlook in the quarter, the softer sales trajectory pushed management to lower its full-year 2026 expectations. (biospace.com)

The key negative catalyst is the forecast reset for 2026. QIAGEN now expects full-year net sales growth of 1%–2% at constant exchange rates, down from its prior expectation of at least 5% growth, and reduced its adjusted diluted EPS outlook to at least $2.43 (from at least $2.50). The update highlights that profitability is holding up better than revenue, but the market is repricing the slower growth profile. (ad-hoc-news.de)

The outlook reduction follows “mixed sales trends,” with weakness tied to lower demand in areas including immigration testing and more cautious U.S. life-sciences spending, alongside a reported decline in QuantiFERON sales. Investors are treating these demand signals as more structural than a one-quarter timing issue, given the full-year cut rather than a narrow tweak. (newsminimalist.com)

QIAGEN scheduled a conference call on Tuesday, April 28, 2026, at 9:30 a.m. New York time to discuss the preliminary Q1 results and the updated 2026 outlook. Traders will focus on whether management frames the demand softness as temporary, whether a second-half rebound is expected, and whether additional product or end-market strength can offset weakness in QuantiFERON and life-sciences spending. (biospace.com)